Do type-2 allergic activation, histamine burden, autoimmune tolerance loss, and omega-6-biased lipid mediators reinforce low-grade immune inflammation?

Chronic low-grade immune inflammation is sustained through a highly cooperative, self-perpetuating network rather than an isolated pathway. When Type-2 allergic activation, histamine burden, autoimmune tolerance loss, and omega-6-biased lipid mediators intersect, they establish a feedback loop that locks the immune system into a persistent inflammatory state.

Mechanistic synergy of immune dysregulation

• Lipid-driven tolerance loss: Omega-6-derived eicosanoids, particularly prostaglandin E2 ($\text{PGE}_2$), act through EP2 and EP4 receptors. This signaling directly disrupts Foxp3 expression and TGF-beta-driven regulatory T (Treg) cell conversion, systematically disabling the body's primary immunological brakes.
• Allergic and helper T-cell skewing: $\text{PGE}_2$ actively promotes Type-2 allergic activation by suppressing Th1-promoting signals like IL-12 and IFN-gamma. Concurrently, elevated histamine acts via H2 receptors on antigen-presenting cells to suppress IL-12 and enhance IL-10 secretion, further skewing CD4+ T-cell differentiation toward a dominant Th2 phenotype.
• Amplified inflammatory signaling: Histamine also signals through H4 receptors ($\text{H}_4\text{R}$) expressed on Th17 and Th2 cells, directly driving the production of the highly pro-inflammatory cytokine IL-17. Together, $\text{PGE}_2$ and IL-1beta promote the expansion of inflammatory Th17.1 cells.
• The self-amplifying cycle: The loss of autoimmune tolerance, characterized by Treg instability and Th1/Th17 expansion, removes regulatory control. Unchecked immune activation causes continuous tissue stress, which in turn triggers further mast cell degranulation, histamine release, and omega-6 lipid mediator synthesis, locking the loop.

Bottom line

• Type-2 allergic activation, histamine burden, omega-6-derived $\text{PGE}_2$, and autoimmune tolerance loss form a closed-loop pathological network. These mediators cooperatively suppress regulatory Tregs while driving Th2 and Th17 inflammatory pathways, trapping the tissue microenvironment in a state of persistent, low-grade immune inflammation.